CARLSBAD, Calif., July 25 /EMWPresswire/ -- AutoGenomics, Inc. today

announced that it has filed a registration statement on Form S-1 with the

Securities and Exchange Commission relating to the proposed initial public

offering of shares of its common stock. The number of shares of common

stock to be offered, all of which are expected to be offered by

AutoGenomics, Inc., and the price range for the offering, have not yet been

determined.



    J.P. Morgan Securities Inc. is acting as sole book-running manager of

the offering, and Deutsche Bank Securities Inc. is acting as co-lead

manager. Pacific Growth Equities, LLC and Robert W. Baird & Co.

Incorporated are acting as co-managers.



    The offering will be made only by means of a prospectus. When

available, copies of the preliminary prospectus relating to this offering

may be obtained by contacting: J.P. Morgan Securities Inc., 4 Chase

Metrotech Center, CS Level, Brooklyn, NY 11245 Attention: Chase

Distribution & Support Service Northeast Statement Processing.



    A registration statement relating to these securities has been filed

with the Securities and Exchange Commission, but has not yet become

effective. These securities may not be sold nor may offers to buy be

accepted prior to the time the registration statement becomes effective.

This press release shall not constitute an offer to sell or the

solicitation of an offer to buy nor shall there be any sale of these

securities in any state in which such offer, solicitation or sale would be

unlawful prior to their registration or qualification under the securities

laws of any such state.

    About AutoGenomics



    AutoGenomics Inc., a privately held company based in Carlsbad, CA, has

developed the first automated, microarray based multiplexing diagnostic

platform that can be used to assess disease signatures with novel genomic

and proteomic markers in the area of genetic disorders, infectious disease,

cancer and pharmacogenetics. With the discovery of genes and their link to

various disease states the platform has the versatility to revolutionize

the way patients are diagnosed, monitored and managed leading to the era of

personalized medicine.